News & Updates
Filter by Specialty:
Exercise, Mediterranean diet remain key against MASLD
A 12-week lifestyle intervention comprising a moderate-intensity physical activity (PA) programme and a hypocaloric Mediterranean diet (MD) promoted fat removal and liver fibrosis improvement in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD), findings from the EHmet-DIA study suggest.
Exercise, Mediterranean diet remain key against MASLD
21 Jun 2024
Seladelpar extends benefit to PBC patients with compensated liver cirrhosis
An interim analysis of the open-label phase III ASSURE study finds benefit in seladelpar, a novel delpar (a potent and selective PPAR*-delta agonist), for individuals with primary biliary cholangitis (PBC) and compensated liver cirrhosis.
Seladelpar extends benefit to PBC patients with compensated liver cirrhosis
20 Jun 2024
Physical activity substantially cuts cirrhosis risk in MASLD patients
A study presented at DDW 2024 showed that adequate physical activity reduces the risk of cirrhosis in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD).
Physical activity substantially cuts cirrhosis risk in MASLD patients
19 Jun 2024
Novel miRNA signature reliably detects lethal pancreatic cancer in the early stages
An exosome-based liquid biopsy showed favourable signals for noninvasive, early detection of pancreatic ductal adenocarcinoma (PDAC) in a prospective study.
Novel miRNA signature reliably detects lethal pancreatic cancer in the early stages
14 Jun 2024
Blood-based CRC screening platform delivers promising performance
An investigational blood-based test performs satisfactorily for the early detection of colorectal cancer (CRC), having met all prespecified primary endpoints in the large PREEMPT CRC trial.
Blood-based CRC screening platform delivers promising performance
13 Jun 2024
Statins may protect against primary sclerosing cholangitis in IBD patients
Patients with inflammatory bowel disease (IBD) who use statins appear to have a substantially reduced risk of primary sclerosing cholangitis (PSC), as shown in a retrospective study.
Statins may protect against primary sclerosing cholangitis in IBD patients
12 Jun 2024
Add-on bispecific antibody may alter treatment landscape of G/GEJ cancer
Adding the PD-1/CTLA-4 bispecific antibody cadonilimab to chemotherapy improves overall survival (OS) and progression-free survival (PFS) in individuals with untreated, HER2-negative, locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer, including patients with PD-L1–low tumours, according to the interim results of the phase III COMPASSION-15 trial.